Form 8-K - Current report:
SEC Accession No. 0001558370-23-002100
Filing Date
2023-02-27
Accepted
2023-02-27 06:36:11
Documents
14
Period of Report
2023-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20230227x8k.htm   iXBRL 8-K 40933
2 EX-99.1 plx-20230227xex99d1.htm EX-99.1 177252
3 GRAPHIC plx-20230227xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-23-002100.txt   363834

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20230227.xsd EX-101.SCH 3263
5 EX-101.LAB plx-20230227_lab.xml EX-101.LAB 16108
6 EX-101.PRE plx-20230227_pre.xml EX-101.PRE 10853
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230227x8k_htm.xml XML 4866
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 23669974
SIC: 2836 Biological Products, (No Diagnostic Substances)